To Evaluate The Growth And Development Of Patients With Oral Propranolol In The Treatment Of Infantile Hemangioma By DDST

objective:To evaluate the growth and development of patients with oral propranolol in the treatment of infantile hemangioma by DDST.Methods:From June 2017 to June2019 patients who were diagnosed with hemangioma in the Maxillofacial Surgery Vascular Disease Specialized Disease Outpatient Departments of the First Affiliated Hospital of Xinjiang Medical University and were treated with propranolol for the first time were collected for this study follow-up.The development and growth of 180 patients treated with oral propranolol were evaluated by DDST screening.Results:The results of DDST evaluation were normal.However,there were significant differences in body weight among low birth weight infants,patients with congenital heart disease,patients with different age of starting medication and different duration of medication(P<0.05),There was a significant correlation between the age of starting medication,the duration of medication and low body weight during screening(P<0.05),the earlier the age of starting medication and the longer the time of medication,the lower the body weight of the patients.There were significant differences in height of low birth weight infants,premature infants,congenital heart diseases and patients with different duration of medication during screening(P<0.05),and the medication duration was abnormal with the height during screening there was a significant correlation(P<0.05),The longer the time of medication,the lower the height of the patients.Conclusion:Oral propranolol may not have any effect on the development of nervous system in patients with IH,but it may affect the height and weight of patients.